Full Text View
Tabular View
Study Results
Related Studies
Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia
This study has been completed.
Study NCT00824512   Information provided by Ipsen

First Received on January 15, 2009.   Last Updated on April 10, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Friedreich Ataxia
Additional conditions recognized in this trial
Ataxia
Stress, Psychological
More general conditions related to this trial
Behavioral Symptoms
Brain Diseases
Central Nervous System Diseases
Cerebellar Diseases
Dyskinesias
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System
Metabolic Diseases
Mitochondrial Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurologic Manifestations
Signs and Symptoms
Spinal Cord Diseases
Spinocerebellar Degenerations
Interventions listed in this trial
EGb 761 120 mg
Placebo
Sponsors listed in this trial
Ipsen


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services